Are there new treatments or clinical trials available for sarcoidosis? 

Sarcoidosis management in the UK is currently undergoing a significant shift, with new biologic therapies becoming available for the first time in decades. While many people with sarcoidosis do not require immediate medical intervention as the condition often resolves on its own, those with persistent or severe symptoms now have access to more targeted options. Understanding these developments, alongside the role of ongoing clinical research, is essential for patients whose symptoms have not responded to traditional therapies. 

What We’ll Discuss in This Article 

• The traditional foundation of sarcoidosis management in the UK. 

• The recent commissioning of Infliximab for refractory pulmonary cases. 

• How biologic therapies work to target specific inflammatory proteins. 

• Promising new drugs currently being evaluated in clinical trials. 

• The role of UK specialist centres in delivering advanced care. 

• How to find and participate in clinical research opportunities. 

Current standard treatments for sarcoidosis in the UK 

Steroids and second line immunosuppressants remain the foundation of care for the majority of patients who require intervention to prevent organ damage. For most individuals, oral corticosteroids like prednisolone are the first treatment tried, as they are effective at rapidly reducing inflammation and slowing the growth of granulomas. The NHS states that most people with sarcoidosis find their symptoms improve without treatment within a few years, but for those with significant organ involvement, these medications are vital. 

When steroids are used for a long period, or if the initial response is insufficient, doctors may introduce “steroid sparing” agents. These drugs, such as methotrexate, azathioprine, or mycophenolate, work by suppressing the immune system in a different way, allowing for a reduction in the steroid dose and its associated side effects. These treatments have been used for decades and are well established in UK clinical practice for managing persistent or chronic sarcoidosis across different organ systems. 

The introduction of biologic therapies like Infliximab 

In a landmark shift, Infliximab has recently been commissioned by NHS England as a targeted biologic therapy for severe cases that have not responded to standard treatments. This development marks the first time a new class of medicine has been officially made available for sarcoidosis patients in over 50 years. NHS England has commissioned Infliximab as a routine treatment option for refractory sarcoidosis, providing a new pathway for those with the most progressive and destructive forms of the disease. 

Infliximab works by neutralising a specific protein in the body called Tumor Necrosis Factor alpha, which is a major driver of the inflammation seen in sarcoidosis. By targeting this protein directly, the treatment can often quieten the immune response more effectively than broader immunosuppressants. This therapy is typically administered as an intravenous infusion in a hospital setting, usually every eight weeks after an initial loading period. It is specifically reserved for patients whose disease remains active despite trying at least two other types of standard medication. 

Comparing standard and advanced treatment options 

The choice between different sarcoidosis treatments depends on the severity of the disease and how well a patient tolerates specific medications. 

Treatment Category	Common Examples	Primary Use
First-Line	Prednisolone (Corticosteroids)	Rapid reduction of acute inflammation and granulomas.
Second-Line	Methotrexate, Azathioprine	Long term management and reducing steroid dependency.
Biologics	Infliximab, Adalimumab	Targeted therapy for severe, refractory disease cases.
Topical/Local	Steroid creams or eye drops	Management of skin lesions or eye inflammation only.

Deciding to move from standard therapies to advanced biologics is a significant clinical step. NICE clinical guidelines suggest that biologics like Infliximab have a specific role in pulmonary sarcoidosis when other options have failed, ensuring that the most intensive treatments are prioritised for those at greatest risk of permanent organ damage or reduced life expectancy. 

Promising new treatments in clinical trials 

Several new therapies, including the anti-inflammatory protein efzofitimod, are currently being evaluated in UK and international clinical trials to provide even more targeted care. These trials are essential because they test medications that work through entirely different biological pathways than existing drugs. For example, some new drugs aim to “nudge” the immune system back into balance rather than broadly suppressing it, which could potentially result in fewer side effects for patients. 

Efzofitimod is one of the most watched developments in the field, with research focusing on its ability to reduce lung inflammation and the progression of permanent scarring. Other trials are investigating the use of inhaled medications, which could deliver treatment directly to the lungs, and new biomarkers that help doctors predict which patients are most likely to benefit from specific drugs. These research efforts are vital for moving toward a more personalised approach to sarcoidosis care, where treatment is tailored to the individual’s unique genetic and molecular profile. 

Participating in sarcoidosis research in the UK 

Patients in the UK can explore clinical trial opportunities through the NIHR and specialist respiratory centres that lead national research initiatives. Participating in a trial can provide access to new treatments before they are widely available and contributes to the global understanding of how to better manage the condition. Most major UK teaching hospitals, particularly those with specialist Interstitial Lung Disease units, are active participants in these studies. 

If you are interested in joining a clinical trial, the first step is to discuss this with your specialist consultant. They can provide information on which trials are currently recruiting and whether your specific type of sarcoidosis meets the criteria for participation. You can also search the NIHR “Be Part of Research” database or check with major UK sarcoidosis charities, which often list active studies and provide information on how to get involved. 

Conclusion 

While steroids remain the primary treatment for sarcoidosis, the landscape of care in the UK is expanding with the introduction of biologic therapies and a surge in clinical research. The recent commissioning of Infliximab by NHS England provides a critical new option for those with severe, refractory disease. As clinical trials continue to investigate even more targeted and gentler therapies, the outlook for managing this complex condition continues to improve. 

If you experience severe, sudden, or worsening symptoms, such as significant chest pain, sudden difficulty breathing, or total collapse, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article was created to provide the public with safe, neutral information on the evolving landscape of sarcoidosis treatment in the UK. It was written and reviewed by Dr. Rebecca Fernandez, a UK-trained physician with extensive experience in internal medicine, cardiology, and emergency care. The content aligns with current NHS England commissioning policies and NICE guidance to ensure medical accuracy and patient safety.